Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia
Richard Vollenberg,
Rabie Jouni,
Peter A. A. Norris,
Monika Burg-Roderfeld,
Nina Cooper,
Mathias J. Rummel,
Gregor Bein,
Irene Marini,
Behnaz Bayat,
Richard Burack,
Alan H. Lazarus,
Tamam Bakchoul,
Ulrich J. Sachs
Affiliations
Richard Vollenberg
Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany
Rabie Jouni
Center for Clinical Transfusion Medicine, Medical Faculty of Tübingen, Eberhard Karls University, Tübingen, Germany
Peter A. A. Norris
The Canadian Blood Services & The Keenan Research Centre of St. Michael’s Hospital, Toronto, ON, Canada
Monika Burg-Roderfeld
Faculty for Chemistry and Biology, Fresenius University of Applied Sciences, Idstein, Germany
Nina Cooper
Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany
Mathias J. Rummel
IVth Department of Internal Medicine (Hematology/Oncology), Justus Liebig University, Giessen, Germany
Gregor Bein
Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany
Irene Marini
Center for Clinical Transfusion Medicine, Medical Faculty of Tübingen, Eberhard Karls University, Tübingen, Germany
Behnaz Bayat
Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany
Richard Burack
Department of Pathology and Laboratory Medicine, University of Rochester, NY, USA
Alan H. Lazarus
The Canadian Blood Services & The Keenan Research Centre of St. Michael’s Hospital, Toronto, ON, Canada
Tamam Bakchoul
Center for Clinical Transfusion Medicine, Medical Faculty of Tübingen, Eberhard Karls University, Tübingen, Germany
Ulrich J. Sachs
Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany;Center for Transfusion Medicine and Hemotherapy and Hemostasis Center, University Hospital Giessen and Marburg, Marburg, Germany
Platelet autoantibody-induced platelet clearance represents a major pathomechanism in immune thrombocytopenia (ITP). There is growing evidence for clinical differences between anti-glycoprotein IIb/IIIa and anti-glycoprotein Ib/IX mediated ITP. Glycoprotein V is a well characterized target antigen in Varicella-associated and drug-induced thrombocytopenia. We conducted a systematic study assessing the prevalence and functional capacity of autoantibodies against glycoprotein V. A total of 1140 patients were included. In one-third of patients, platelet-bound autoantibodies against glycoproteins Ib/IX, IIb/IIIa, or V were detected in a monoclonal antibody immobilization of platelet antigen assay; platelet-bound autoantiglycoprotein V was present in the majority of samples (222 out of 343, 64.7%). Investigation of patient sera revealed the presence of free autoantibodies against glycoprotein V in 13.5% of these patients by an indirect monoclonal antibody immobilization of platelet antigen assay, but in 39.6% by surface plasmon resonance technology. These antibodies showed significantly lower avidity (association/dissociation ratio 0.32±0.13 vs. 0.73±0.14; P
